ConductScience.org, home

Comparison · NCT03518034-3af6284d

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Cancer

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Cancer. Trial comparisons, record NCT03518034-3af6284d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03518034-3af6284d

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.004620.002650.00806wilson
Risk in group 20.004230.002360.00755wilson
Risk difference, group 1 minus group 20.000395-0.003470.00431newcombe hybrid score
Risk ratio, group 1 over group 21.090.4832.47log
Odds ratio, group 1 over group 21.090.4822.48log
Number needed to treat, for one more participant with the outcome on AndroGel 1.62% than on Placebo2,530from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1AndroGel 1.62%
Participants received topical testosterone starting with a 40.5 mg dose (2 pump actuations) of the study drug OD. Participants may have received a dose in the range of 20.25 mg (1 actuation) to 101.25 mg (5 actuations) in 20.25 mg increments during the course of the study if titrations were necessary.
122,596OG000
Group 2PlaceboParticipants received matching placebo OD.112,602OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Tertiary Endpoint: Incidence Rate of Prostate Cancer
Description
Presented as the number and percentage of participants who with prostate cancer, as adjudicated by Prostate Safety Events Committee (PAC).
Time frame
Randomization to event or last known date if no event (up to approximately 52 months).
Population
TRAVERSE Main Study Safety Set: all randomized participants who received at least one dose of study drug and have no duplicate/triplicate participant IDs.

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
NCT number
NCT03518034
Phases
PHASE4
Conditions
Hypogonadism, Cardiovascular Diseases
Interventions
AndroGel®, Placebo
Lead sponsor
AbbVie
Results first posted
2024-03-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03518034-3af6284d